UK markets closed

Valneva SE (VALN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.95+0.10 (+0.92%)
As of 02:03PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close10.85
Bid10.95 x 1200
Ask11.11 x 1100
Day's range10.84 - 11.05
52-week range9.07 - 17.05
Avg. volume4,695
Market cap797.25M
Beta (5Y monthly)0.93
PE ratio (TTM)60.83
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million

    Saint Herblain (France), September 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®. Under this new one-year contract, the DoD will buy a minimum of $32 million worth of IXIARO® vaccines and has the possibility to purchase additional doses during the coming twelve months. Delive

  • Globe Newswire

    Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

    Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited from a continued recovery of the travel industry as well as from price increasesBringing total revenues to €73.7 million in the first half of 2023 Strong cash position of €204.4 million as at June 30, 2023 Excludes up to an additional $100 million made available as part of a recent upsized financing arrangemen

  • Globe Newswire

    Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

    Strong immune response shown in both children and adolescents one month after booster dose (month 19) in VLA15-221 studyPreviously observed high anamnestic antibody response in adults confirmedVLA15 well-tolerated in all age groups following booster dose Saint-Herblain (France) & New York, September 7, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine ca